Expert Perspectives in the Recognition and Management of Postpartum Depression
View More
Southern California Psychiatry Conference
July 11-12, 2025
Register Now!
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists
View More
BURST CME™ Part I: Understanding the Impact of Huntington’s Disease
View More
Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease
View More
Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea
View More
Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment
View More
PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia
View More
Southern Florida Psychiatry Conference
November 21-22, 2025
Register Now!
Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?
View More
Optimizing Care for Patients With Tardive Dyskinesia
View More
Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia
View More
Recurrent Brief Mixed Depression
December 31st 2013This case study of a 21-year-old woman-referred by a relative because of long-standing severe interpersonal, academic, and occupational impairment-illustrates the importance of screening patients with brief episodes of depression for mixed features.
Read More
Benzodiazepines vs Antidepressants for Anxiety Disorders
December 19th 2013A recent systematic review and meta-analysis that compared benzodiazepines with antidepressants for anxiety disorders has triggered a debate among clinicians about first-line treatments, efficacy for specific disorders, and adverse effects.
Read More
Risperdal Maker Pays High Price to Resolve Criminal and Civil Investigations
November 8th 2013Johnson & Johnson and its subsidiaries will pay more than $2.2 billion to resolve criminal and civil liability arising from allegations relating to the prescription drugs Risperdal, Invega and Natrecor, including promotion for uses not approved as safe and effective by FDA and payment of kickbacks to physicians and to the nation’s largest long-term care pharmacy provider.
Read More
“Switching” of Mood From Depression to Mania With Antidepressants
Mood switching is not uncommon and it is much more prevalent in depressed juveniles than in depressed adults, and there is a large apparent excess of antidepressant-associated switching over reported spontaneous diagnostic changes to bipolar disorder. Details here.
Read More
A Risk Stratification Approach to Alcohol Detoxification
November 5th 2013The challenges of identifying patients at risk for alcohol withdrawal have been found to be mitigated by the development of a Risk Stratification Questionnaire, now being adopted by the VA regionally throughout New England. More in this video.
Read More
Panic Disorder: Keys to Evidence-Based Effective Treatment
October 30th 2013Keys to the management of panic disorder include appropriate use of psychotropic medication and psychotherapy predicated on an understanding of the disorder's biopsychosocial underpinnings. Here, Stephen V. Sobel, MD, focuses on treatment options.
Read More
Warning: Antidepressants May Cause Bank Robbery
September 27th 2013Some attorneys have argued that SSRIs cause serious adverse events, capable of compelling defendants to engage in strikingly complex criminal behavior. On close examination, however, these phenomena may be clearly distinguished from criminal behavior.
Read More
Catching Up on Sleep: From Comorbidity to Pharmacotherapy
August 26th 2013More than half of all patients with psychiatric disorders report disturbances of sleep and wakefulness. "Sleep disorders are associated with impaired daytime function and predict a heightened future vulnerability to psychiatric disease. They also diminish life span.” Details from an expert here.
Read More
Obesity in Patients With Psychiatric Conditions
July 11th 2013Obesity is one of the most common physical health problems in individuals with psychiatric conditions and contributes to excess medical morbidity and mortality. Several classes of psychotropic medications, particularly atypical antipsychotics, cause weight gain. While these issues pose challenges to optimal health, the good news is that there are solutions and emerging strategies.
Read More
Hypothyroidism: An Important Diagnostic Consideration for the Psychiatrist
July 11th 2013Hypothyroidism is a common clinical disorder that psychiatrists frequently encounter. However, symptoms of thyroid dysfunction are often vague and nonspecific, which can lead to delayed or missed diagnosis.
Read More
No Mortality Increase With Antipsychotics in Prospective Study
June 17th 2013Results of a 10-week prospective study, recently reported at the Annual Meeting of the American Association for Geriatric Psychiatry, offered no conclusive evidence about the mortality risk of elderly patients with Alzheimer disease who were treated with antipsychotics.
Read More